A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas (Q45094655)

9 December 2017

title

A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas (English)

1 reference

9 December 2017

0 references

7

1 reference

9 December 2017

8

George Fountzilas

1 reference

9 December 2017

2

Vassiliki Kotoula

1 reference

9 December 2017

George Pentheroudakis

series ordinal

3

object named as

George Pentheroudakis

1 reference

9 December 2017

6

Sofia Chrisafi

1 reference

9 December 2017

5

Sofia Lambaki

1 reference

9 December 2017

4

Despina Televantou

1 reference

9 December 2017

Vasilios Karavasilis

1

1 reference

9 December 2017

publication date

5 January 2013

1 reference

9 December 2017

1 reference

9 December 2017

volume

260

1 reference

9 December 2017

issue

6

1 reference

9 December 2017

page(s)

1469-1480

1 reference

Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats.

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Molecular targeting of glioblastoma: Drug discovery and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

The transcriptional network for mesenchymal transformation of brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Glioblastoma multiforme and the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Amplification of Epidermal Growth Factor Receptor Gene in Gliomas: Histopathology and Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Mechanisms of disease: temozolomide and glioblastoma--look to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Genetic profile of astrocytic and oligodendroglial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Lapatinib for advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Molecular diagnostics of gliomas: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Amplification and differential expression of members of the erbB-gene family in human glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Bevacizumab in glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Individualized targeted therapy for glioblastoma: fact or fiction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00415-012-6812-Z

Reverse transcriptase polymerase chain reaction as a reliable method to detect epidermal growth factor receptor exon 2-7 gene deletion in human glioblastomas

21 January 2018

1 reference

12 December 2020

Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.

1 reference

12 December 2020

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

1 reference

12 December 2020

What is the relevance of determining EGFR-variant-III status in glioblastomas?

1 reference

12 December 2020

Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis

1 reference

12 December 2020

10.1007/S00415-012-6812-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

9 December 2017

1028459988

0 references

1 reference